COIOSDeep risk insights through multi-disciplinary research across the globe
Snow on windowsill with glowing lights outside
Item refines Preprint · not peer-reviewed Added

COVID-19 antibody levels overstate protection in people on immunosuppressive therapy

Binding antibody levels after mRNA vaccination were 54.5 times lower in people on B-cell depleting drugs than in healthy controls, and protection was lower at any given antibody level.

The review pooled binding antibody levels after mRNA vaccination in people on immunosuppressive therapy for blood cancers, neurological and rheumatic conditions, against healthy controls. Levels were lowest in those on B-cell depleting drugs, 54.5 times lower than in healthy controls. Set against vaccine effectiveness measured earlier in people with the same conditions, protection rose with antibody level but stayed lower in the immunosuppressed throughout.

Why it is interesting: Antibody level is the standard correlate of protection, and here it overstates the protection seen.

Source
medRxiv, 22 September 2026
Paper
Immunogenicity and vaccine effectiveness of COVID-19 vaccines in people on immunosuppressive therapies
Authors
Stadler E, Khan SR, Elias KM, Egilmezer E, Phetsouphanh C, Hastak P et al.
DOI
10.64898/2026.09.16.26363194
Type
Preprint
Design
Systematic review and meta-analysis of post-mRNA-vaccination binding antibody levels across immunosuppressive therapy cohorts and healthy controls, linked to existing vaccine effectiveness estimates
Verdict
Refines prior evidence
Driver
Infection and pandemics
Abstract — the authors' own words, CC BY

Neutralizing antibodies are a correlate of protection (CoP) of SARS-CoV-2 vaccine efficacy. However, data informing CoPs often explicitly exclude people on immunosuppressive therapies who are at an increased risk of symptomatic and severe COVID-19, delayed viral clearance, and death. Investigating the relationship between antibodies and protection for people on immunosuppressive therapies could provide insights into mechanisms of protection. We performed a systematic search to identify studies reporting SARS-CoV-2 binding antibody levels after mRNA vaccination in people with hematological malignancies, neurological disorders, rheumatic diseases, and mixed immune-mediated inflammatory disorders (IMIDs) on immunosuppressive therapies including B-cell depletion, JAK inhibitors, and S1P inhibitors, as well as healthy controls. Binding antibody levels varied between cohorts receiving different immunosuppressive treatments. Compared to healthy controls the lowest antibody levels were observed in subjects treated with B-cell depletion (54.5-fold reduction, 95% CI: 34.5-86.2) and S1P inhibitors (24.8-fold reduction, 95% CI: 13.2-46.7). To assess the association between antibody level and protection, we used data from a previous study of COVID-19 vaccine effectiveness in people with the same underlying conditions. We linked vaccine effectiveness estimates with the predicted antibody level in people on immunosuppressive therapies (using antibody data including this meta-analysis of binding antibody levels). Predicted neutralizing antibody levels were correlated with vaccine effectiveness both for infection and hospitalization (p<0.0001 and p<0.0001, respectively). However, we found that for any given antibody level, people who are immunosuppressed had lower protection against infection and hospitalization than a healthy population.

Other drivers in Behavioural science